Skip to content

Study · Animal study (in vivo) · mouse and rat · 2002

6 results

[Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)].

Kovalenko LP, Miramedova MG, Alekseeva SV, Gudasheva TA, Ostrovskaia RU, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2002Cited by 1 (Europe PMC)

PMID12109295 (opens in a new tab)PepBankPUB-12109295
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In CBA mice, single or prolonged noopept administration dose-dependently inhibited the inflammatory response to concanavaline A.

    In plain wordsIn mice, noopept inhibited inflammation from concanavaline A in a dose-dependent manner.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseConcanavaline A inflammatory response
    Study

    mousen: not reported in source

    CBA mice with concanavaline A inflammation
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    single intravenous 0.5 or 5 mg/kg, single oral 10, 50 or 100 mg/kg, or prolonged oral 5 mg/kg · intravenous or oral (source also labels intravenous doses p.o.) · single administration or 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    It is established that single intravenous (0.5 and 5 mg/kg, p.o.) or single peroral (10, 50, 100 mg/kg) and prolonged peroral (5 mg/kg, over 10 days) administration of noopept produces a dose-dependent inhibition of the model inflammatory response to concanavaline A in CBA mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intravenous noopept suppressed carrageenan-induced foot inflammation by 62.2% within 3 hours.

    In plain wordsIn rats, intravenous noopept reduced foot inflammation from carrageenan by 62.2% within 3 hours.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseCarrageenan foot inflammation
    Study

    ratn: not reported in source

    acute nonimmune carrageenan-induced foot inflammation
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    5 mg/kg · intravenousAs given in this study (rat).

    Measurements

    Inflammation suppression
    62.2%
    within 3 h

    Source sentences

    Summary
    Intravenously injected (5 mg/kg) noopept suppressed the acute nonimmune carrageenan-induced foot inflammation in rats by 62.2% within 3 h.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with adjuvant arthritis, intramuscular noopept reduced chronic immune inflammation by 94.0% on day 12.

    In plain wordsIn rats with arthritis, intramuscular noopept reduced chronic inflammation by 94.0% on day 12.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseAdjuvant arthritis inflammation with intramuscular dosing
    Study

    ratn: not reported in source

    adjuvant arthritis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.5 mg/kg daily · intramuscular · 25 daysAs given in this study (rat).

    Measurements

    Inflammation reduction
    94%
    0.5 mg/kg i.m., 12th day

    Source sentences

    Summary
    The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with adjuvant arthritis, oral noopept reduced chronic immune inflammation by 74.1% on day 12.

    In plain wordsIn rats with arthritis, oral noopept reduced chronic inflammation by 74.1% on day 12.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseAdjuvant arthritis inflammation with oral dosing
    Study

    ratn: not reported in source

    adjuvant arthritis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    5 mg/kg daily · oral · 25 daysAs given in this study (rat).

    Measurements

    Inflammation reduction
    74.1%
    5 mg/kg p.o., 12th day

    Source sentences

    Summary
    The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively).
  5. 05LabEx vivo tissueMechanism

    In leukocytes from noopept-treated mice, zymosan-stimulated hemiluminescence showed a 5- to 6-fold suppression.

    In plain wordsIn lab tests of cells from treated mice, noopept suppressed zymosan-stimulated hemiluminescence 5- to 6-fold.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseZymosan-stimulated hemiluminescence
    Study

    mousen: not reported in source

    neutrophilic leukocytes from F1(CBA.C57BL/6) mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    5 mg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    The in vitro experiments with neutrophilic leukocytes of F1(CBA.C57BL/6) mice treated with noopept in a single dose of 5 mg/kg (i.v.) showed a 5- to 6-fold suppression of the hemiluminescence stimulated by opsoinized zymosan or phorbolmyristate acetate.
  6. 06LabEx vivo tissueMechanism

    In leukocytes from noopept-treated mice, phorbolmyristate acetate-stimulated hemiluminescence showed a 5- to 6-fold suppression.

    In plain wordsIn lab tests of cells from treated mice, noopept suppressed phorbolmyristate acetate-stimulated hemiluminescence 5- to 6-fold.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreasePhorbolmyristate acetate-stimulated hemiluminescence
    Study

    mousen: not reported in source

    neutrophilic leukocytes from F1(CBA.C57BL/6) mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    5 mg/kg · intravenousAs given in this study (mouse).

    Source sentences

    Summary
    The in vitro experiments with neutrophilic leukocytes of F1(CBA.C57BL/6) mice treated with noopept in a single dose of 5 mg/kg (i.v.) showed a 5- to 6-fold suppression of the hemiluminescence stimulated by opsoinized zymosan or phorbolmyristate acetate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.